期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms21010141
关键词
drug targets/oncoprotein and tumor suppressor drug targets; drug mechanisms; cell signaling/guanine nucleotide binding proteins and effectors; oncogenes and tumor suppressors/KRAS
资金
- National Cancer Institute (NCI) [R01CA131378, R01CA148817, R01CA197147, R01CA155638]
- University of South Alabama Mitchell Cancer Institute
Oncogenic mutations in RAS genes result in the elevation of cellular active RAS protein levels and increased signal propagation through downstream pathways that drive tumor cell proliferation and survival. These gain-of-function mutations drive over 30% of all human cancers, presenting promising therapeutic potential for RAS inhibitors. However, many have deemed RAS undruggable after nearly 40 years of failed drug discovery campaigns aimed at identifying a RAS inhibitor with clinical activity. Here we review RAS nucleotide cycling and the opportunities that RAS biochemistry presents for developing novel RAS inhibitory compounds. Additionally, compounds that have been identified to inhibit RAS by exploiting various aspects of RAS biology and biochemistry will be covered. Our current understanding of the biochemical properties of RAS, along with reports of direct-binding inhibitors, both provide insight on viable strategies for the discovery of novel clinical candidates with RAS inhibitory activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据